FindTrial
Sign In

A study to find out whether a score based on simple blood test results (protein and bilirubin levels) can help predict how well patients recover and how long they survive after liver cancer surgery.

Prognostic value of the Albumin Bilirubin (ALBI) grade in patients undergoing surgery for hepatocellular carcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099258
Enrollment
400
Registered
2025-12-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C221- Intrahepatic bile duct carcinoma

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients (18 years of age and above) who underwent curative-intent hepatectomy for hepatocellular carcinoma with complete clinical and surgical data, along with preoperative liver function parameters including serum albumin and bilirubin measured within one week prior to surgery.

Exclusion criteria

Exclusion criteria: Patients with prior liver transplantation, palliative resections, or incomplete records

Design outcomes

Primary

MeasureTime frame
To evaluate the sensitivity and specificity of ALBI score in predicting post-hepatectomy liver failure (PHLF)Timepoint: 6 MONTHS—

Secondary

MeasureTime frame
Independent predictive accuracy of ALBI score for OS and DFSTimepoint: 6 months;Cut-off of ALBI score predicting worse postoperative and/or survival outcomesTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Mahesh Goel

Tata Memorial Hospital, Mumbai

drmaheshgoel@gmail.com9820504492

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026